[Development of quality of life (QOL) questionnaire for use of lung cancer patients in palliative therapy--study of validity and reliability no. 2, the effects of chemotherapeutics in QOL].
The effects of cisplatin and carboplatin in QOL were studied using a QOL questionnaire seeking to conform their validity and reliability in lung cancer patients. The questionnaire was composed of eleven items; appetite, feeling, sleep, mental fatigue, pain, anxiety, daily activity, abdominal and respiratory conditions, linear analog and face scale as global scale. The data were collected from 21 patients treated with cisplatin (Cis group) and 9 patients administered carboplatin (Carbo group). Chronological changes of QOL were measured by AUC (area under the curve) method. 1) The total score of 9 items, linear analog and face scales rose immediately to the highest levels (worse) after treatment and maintained this level for 1 week in the Cis group. The Carbo group levels rose from 3 days and returned to the control level at 9 days after treatment. 2) AUC of the total score, linear analog and face scales in the Cis group increased significantly when compared with those of the Carbo group. 3) When compared with the Cis and Carbo groups the physiological and active scales were not different, but the psychological scale showed a significant difference between the two groups. 4) The total score of the psychological scale correlated the abdominal score in the Cis group, but not in the Carbo group. 5) Sleep and mental fatigue were related to the aggravation of QOL at 5-6 days after Carboplatin treatment. These results suggested that this QOL questionnaire had sufficient sensitivity to reflect any chemotherapeutic side-effects. 6) AUC is useful method in chronological evaluation of QOL.
Ishihara
Y
Y
Dept. of Hygiene & Public Health, Tokyo Women's Medical College.
Sakai
H
H
Nukariya
N
N
Kobayashi
K
K
Yoneda
S
S
Matsuoka
R
R
Hojou
N
N
Nishiwaki
Y
Y
Hoshi
A
A
Kuratomi
Y
Y
D000328:Adult; D000368:Aged; D001007:Anxiety; D001066:Appetite; D016190:Carboplatin / Q000009:adverse effects*; D002945:Cisplatin / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000523:psychology*; D008297:Male; D005222:Mental Fatigue; D008875:Middle Aged; D010166:Palliative Care; D011788:Quality of Life; D015203:Reproducibility of Results; D012890:Sleep; D011795:Surveys and Questionnaires
D016190:Carboplatin; D002945:Cisplatin